chr9-2086856-G-C
Variant summary
Our verdict is Pathogenic. Variant got 13 ACMG points: 13P and 0B. PM1PM2PM5PP2PP3_StrongPP5_Moderate
The NM_003070.5(SMARCA2):c.2554G>C(p.Glu852Gln) variant causes a missense change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. E852D) has been classified as Likely pathogenic.
Frequency
Consequence
NM_003070.5 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 13 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
SMARCA2 | NM_003070.5 | c.2554G>C | p.Glu852Gln | missense_variant | 18/34 | ENST00000349721.8 | NP_003061.3 | |
SMARCA2 | NM_001289396.1 | c.2554G>C | p.Glu852Gln | missense_variant | 18/34 | NP_001276325.1 | ||
SMARCA2 | NM_139045.4 | c.2554G>C | p.Glu852Gln | missense_variant | 18/33 | NP_620614.2 | ||
SMARCA2 | NM_001289397.2 | c.2554G>C | p.Glu852Gln | missense_variant | 18/33 | NP_001276326.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
SMARCA2 | ENST00000349721.8 | c.2554G>C | p.Glu852Gln | missense_variant | 18/34 | 5 | NM_003070.5 | ENSP00000265773.5 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 31
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
SMARCA2-related BAFopathy Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Jun 10, 2021 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at
Publications
No publications associated with this variant yet.